Single Inhibitors Versus Dual Inhibitors: Role of HDAC in Cancer

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2023 May 22

PMID 37214715

Authors

Rubi Roy

Tasnim Ria

Debapriya RoyMahapatra

Ugir Hossain Sk

Affiliations

Soon will be listed here.

Abstract

Due to the multimodal character of cancer, inhibition of two targets simultaneously by a single molecule is a beneficial and effective approach against cancer. Histone deacetylase (HDAC) was widely investigated as a novel category of anticancer drug targets due to its crucial role in various biological processes like cell-proliferation, metastasis, and apoptosis. Numerous HDAC inhibitors such as vorinostat and panobinostat are clinically approved but have limited usage due to their low efficacy, nonselectivity, drug resistance, and toxicity. Therefore, HDACs with a dual targeting ability have attracted great attention. The strategy of combining a HDAC inhibitor with other antitumor agents has been proved advantageous for combating the nonselectivity and drug resistivity problems associated with single-target drugs. Henceforth, we have highlighted dual-targeting inhibitors to target HDAC along with topoisomerase, receptor tyrosine kinase inhibitors, and the zeste homolog 2 enzyme. Our Review mainly focuses on the impact of the substituent effect along with the linker variation of well-known HDAC-inhibitor-conjugated anticancer drugs.

Citing Articles

Anticancer efficacy of Spiruchostatin A: current insights into histone deacetylase inhibition and oncologic applications.

Ibrahim S, Khan M, Khurram I, Ghani M, Sharifi-Rad J, Calina D Eur J Med Res. 2025; 30(1):169.

PMID: 40082963 PMC: 11907871. DOI: 10.1186/s40001-025-02401-0.

Histone deacetylase inhibitors for leukemia treatment: current status and future directions.

Hosseini M, Sanaat Z, Akbarzadeh M, Vaez-Gharamaleki Y, Akbarzadeh M Eur J Med Res. 2024; 29(1):514.

PMID: 39456044 PMC: 11515273. DOI: 10.1186/s40001-024-02108-8.

Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer.

Bollmann L, Lange F, Hamacher A, Biermann L, Schaker-Hubner L, Hansen F Cancers (Basel). 2024; 16(19).

PMID: 39409994 PMC: 11476342. DOI: 10.3390/cancers16193374.

Kuwanon C Inhibits Tumor Cell Proliferation and Induces Apoptosis by Targeting Mitochondria and Endoplasmic Reticulum.

Yuan G, Qian P, Chen L, He N Int J Mol Sci. 2024; 25(15).

PMID: 39125863 PMC: 11312418. DOI: 10.3390/ijms25158293.

Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth.

Jung M, Nicholas N, Grindrod S, Dritschilo A PLoS One. 2024; 19(7):e0306168.

PMID: 39008483 PMC: 11249239. DOI: 10.1371/journal.pone.0306168.

References

Oki Y, Kelly K, Flinn I, Patel M, Gharavi R, Ma A . CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017; 102(11):1923-1930. PMC: 5664396. DOI: 10.3324/haematol.2017.172882. View

Paris M, Porcelloni M, Binaschi M, Fattori D . Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008; 51(6):1505-29. DOI: 10.1021/jm7011408. View

Cincinelli R, Musso L, Artali R, Guglielmi M, La Porta I, Melito C . Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents. PLoS One. 2018; 13(10):e0205018. PMC: 6177136. DOI: 10.1371/journal.pone.0205018. View

Lu D, Yan J, Wang L, Liu H, Zeng L, Zhang M . Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives. ACS Med Chem Lett. 2017; 8(8):830-834. PMC: 5554914. DOI: 10.1021/acsmedchemlett.7b00172. View

Sun D, Zhao Y, Zhang S, Zhang L, Liu B, Ouyang L . Dual-target kinase drug design: Current strategies and future directions in cancer therapy. Eur J Med Chem. 2020; 188:112025. DOI: 10.1016/j.ejmech.2019.112025. View

Landsburg D, Barta S, Ramchandren R, Batlevi C, Iyer S, Kelly K . Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol. 2021; 195(2):201-209. DOI: 10.1111/bjh.17730. View

Weil M, Chen A . PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 2011; 35(1):7-50. PMC: 3063418. DOI: 10.1016/j.currproblcancer.2010.12.002. View

Shaker B, Ahmad S, Lee J, Jung C, Na D . In silico methods and tools for drug discovery. Comput Biol Med. 2021; 137:104851. DOI: 10.1016/j.compbiomed.2021.104851. View

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

10.

Pawelczyk A, Sowa-Kasprzak K, Olender D, Zaprutko L . Molecular Consortia-Various Structural and Synthetic Concepts for More Effective Therapeutics Synthesis. Int J Mol Sci. 2018; 19(4). PMC: 5979569. DOI: 10.3390/ijms19041104. View

11.

Mahboobi S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T . Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J Med Chem. 2010; 53(24):8546-55. DOI: 10.1021/jm100665z. View

12.

Hesham H, Lasheen D, Abouzid K . Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer. Med Res Rev. 2018; 38(6):2058-2109. DOI: 10.1002/med.21505. View

13.

Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A . Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds. Chem Rec. 2018; 18(12):1818-1832. PMC: 7410397. DOI: 10.1002/tcr.201800091. View

14.

Ivasiv V, Albertini C, Goncalves A, Rossi M, Bolognesi M . Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. Curr Top Med Chem. 2019; 19(19):1694-1711. DOI: 10.2174/1568026619666190619115735. View

15.

Sergina N, Moasser M . The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007; 13(12):527-34. PMC: 3035105. DOI: 10.1016/j.molmed.2007.10.002. View

16.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J . Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487(7408):500-4. PMC: 3711467. DOI: 10.1038/nature11183. View

17.

Thomas S, Brugge J . Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997; 13:513-609. DOI: 10.1146/annurev.cellbio.13.1.513. View

18.

Huang L, Fu L . Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015; 5(5):390-401. PMC: 4629442. DOI: 10.1016/j.apsb.2015.07.001. View

19.

Peng F, Xuan J, Wu T, Xue J, Ren Z, Liu D . Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC. Eur J Med Chem. 2016; 109:1-12. DOI: 10.1016/j.ejmech.2015.12.033. View

20.

Jeong W, Doroshow J, Kummar S . United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer. 2013; 37(3):110-44. PMC: 3761410. DOI: 10.1016/j.currproblcancer.2013.06.001. View